CIGS Thin-Film Solar Cells Market Projected to Garner Significant Revenues by 2026 End

The CIGS Thin-Film Solar Cells Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Global CIGS Thin-Film Solar Cells Market: Drivers and Restrains

The increasing market of solar panels and cost efficiency of electricity generated by solar panels as compared to other sources of energy is driving the CIGS thin-film solar cells market. Also the increased efficiency of CIGS thin film solar cells and the reduced time required to produce the electricity as compared to its counterpart’s technologies is further contributing in the growing CIGS thin-film solar cells market. Moreover, the rising concerns amongst people for environmental safety is bolstering the CIGS thin-film solar cells market.

However, the initial high cost of CIGS thin film solar cells and the complexity and technicality associated with its manufacturing can hamper the growth of global CIGS thin-film solar cells market.

 A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12502

Global CIGS Thin-Film Solar Cells Market: Region Wise Outlook

The global CIGS thin-film solar cells market can be divided into seven regions, namely North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa. North America is a dominant region in the global CIGS thin-film solar cells market owing to its presence in the energy and power sector. Asia Pacific ranks second in the market share of global CIGS thin-film solar cells market because of the growing electronics and electrical industry. The flourishing automobiles industry in Europe is the major cause to map this region in the global CIGS thin-film solar cells market. Latin America is also gaining importance in this market due to the investments of this region in the energy and power sector. Middle east and Africa is at a nascent stage in the global CIGS thin-film solar cells market but is anticipated to have a considerable CAGR in the forecasted period.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/12502

Global CIGS Thin-Film Solar Cells Market: Key Players

Some of the key players in the global CIGS thin-film solar cells market are:

  • Trina Solar Limited
  • Tata Power Solar Systems Limited
  • Suniva Inc
  • SolarWorld AG
  • Pionis Energy Technologies LLC
  • JinkoSolar Holding Co. Ltd
  • Borg Inc
  • Alps Technology Inc
  • Itek Energy

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Velocify Announces Elite Award Winners, Whose Sales Breakthroughs Inspired Top-Level Performance

LOS ANGELES, March 14, 2017 /PRNewswire/ — Velocify, the leading sales acceleration platform, today announced its inaugural 2017 Elite Award winners, recognizing customers who made sales acceleration breakthroughs that inspire top-level performance. The award winners – First Direct Lending, Plymouth Rock Assurance, and Southern Careers Institute – shared stories of data-driven accomplishments using the Velocify platform to make leaps beyond past performance and industry norms.

„We want to do more than provide powerful sales technology; we want to uncover and promote new ways for sales organizations to improve performance; our customers play a key role in this effort,” said Velocify CEO and President Nick Hedges. „The 2017 Velocify Elite Award winners offer excellent examples that can help all companies that want the best results from their sales teams.”

Velocify Awards Winners’ Performance Highlights:

First Direct Lending, a direct-to-consumer mortgage lender, launched in 2014 with a single office and just five loan consultants using Velocify. Since launching they have leveraged the sales acceleration platform to grow to more than 175 users in three offices across the country.

With Velocify, the lender was able to test contact and email strategies, quickly on-board and train new salespeople, easily integrate with new marketing partners, and measure campaign and user performance – all without drawing on precious IT resources. First Direct Lending, which is currently licensed in 26 states, describes Velocify as the „central location for ensuring we give customers a great experience, while maximizing sales efficiency.”

The property and casualty insurance carrier Plymouth Rock Assurance, described how Velocify helped the sales team get maximum value out of thousands of purchased leads each month, dramatically improving performance year over year. Using Velocify’s Dial-IQ, Shotgun Connect, and Priority View capabilities, Plymouth Rock cut its response times from hours to seconds and enabled trainers to spend more time coaching reps on how to talk with customers rather than continually reviewing follow-up best practices. After adding these new capabilities in 2014, the insurer saw quotes issued rise 103 percent and sales go up 66 percent the following year. In 2016 Plymouth Rock continued to build momentum with a six percent increase in quotes and another 10 percent increase in sales.

Finally, Southern Careers Institute (http://scitexas.edu), which provides employer-tailored education across business, medical, skilled-trades, technology and cosmetology programs, shared how Velocify was central to nurturing relationships with prospective students and winning back former students. SCI experienced a 15 percent year-over-year increase in enrollments in 2016, and was able to add key integrations and new processes with Velocify for its core campuses, online classes, and technology boot camps.

Each of the Velocify Elite Award winners will be celebrated at an upcoming award ceremony at LeadsCon Las Vegas, March 20-22 at the Paris Hotel Las Vegas. The award ceremony will be held at on March 21st at 5 p.m. at the Velocify booth.

About Velocify
Velocify® is the leading sales acceleration platform. The company helps more than 1,500 sales teams sell more by streamlining and optimizing the sales process from start to finish. Velocify’s platform helps sales teams prospect with more precision, accelerate lead engagement, and implement effective workflows, ultimately helping sales teams find and convert more leads.

Velocify was voted the best software for sales teams by customers on G2Crowd and has been recognized as one of the fastest growing companies in North America by Deloitte and Inc. For more information about Velocify or its technology, please visit the company’s website and blog, or follow the company on Facebook, Twitter, LinkedIn, or YouTube.

 

SOURCE Velocify

UMC and Synopsys Collaboration Speeds 14-nm Custom Design

MOUNTAIN VIEW, Calif. and HSINCHU, Taiwan, March 14, 2017 /PRNewswire/ —

Highlights:

Synopsys, Inc. (Nasdaq: SNPS) and United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (UMC) today announced that the two companies have worked together to enable Synopsys Custom Compiler and Laker® custom design tools to be used with UMC’s 14-nanometer (nm) FinFET process. The enablement collaboration included creating and validating a UMC 14-nm industry-standard iPDK. This iPDK enables full support of the Custom Compiler visually-assisted layout flow, including groundbreaking features that reduce the time it takes for users to layout and connect FinFET devices. The Custom Compiler solution integrates with Synopsys circuit simulation, physical verification and digital implementation tools to provide UMC 14-nm process users with a complete custom design solution.

„We have a long history of working with Synopsys to provide iPDKs for our customers,” said T.H. Lin, director of the IP Development and Design Support division at UMC. „This new 14-nanometer iPDK enables layout designers, including our own internal team, to use Synopsys’ custom design tools for FinFET layout productivity. We are pleased to offer this resource to help customers streamline their design-in process on our volume-production 14-nanometer technology.”

„FinFET process technology is becoming very popular with our customers, but FinFET layout can be a challenge,” said Bijan Kiani, vice president of product marketing at Synopsys. „We collaborated with UMC to enable Custom Compiler for their 14-nanometer process, so UMC customers can use Custom Compiler’s visually-assisted layout to improve FinFET layout productivity.”

Availability

The 14-nm and other process iPDKs for Synopsys Laker and Custom Compiler design tools are available on request from UMC.

About Custom Compiler

Custom Compiler provides an open environment spanning schematics, simulation analysis and layout. Unified with Synopsys’ circuit simulation, physical verification and digital implementation tools, Custom Compiler provides a comprehensive custom design solution. Custom Compiler shortens the time it takes to complete FinFET design tasks from days to hours. Its visually-assisted automation leverages the graphical use model familiar to layout designers while eliminating the need to write complicated code and constraints. With Custom Compiler, routine and repetitive tasks are dealt with automatically without extra setup. Custom Compiler’s visually-assisted automation provides four types of assistants: Layout, In-Design, Template and Co-Design. Layout Assistants speed layout with user-guided automation of placement and routing. In-Design Assistants reduce design iterations by catching physical and electrical errors before signoff verification. Template Assistants help designers reuse existing know-how by making it easy to apply previous layout decisions to new designs. Co-Design Assistants combine the IC Compiler™ place-and-route solution and Custom Compiler into a unified solution for custom and digital implementation. Custom Compiler is based on the industry standard Open Access database. For more information about Custom Compiler, visit www.customcompiler.info.

About Synopsys

Synopsys, Inc. (Nasdaq: SNPS) is the Silicon to Software partner for innovative companies developing the electronic products and software applications we rely on every day. As the world’s 15th largest software company, Synopsys has a long history of being a global leader in electronic design automation (EDA) and semiconductor IP and is also growing its leadership in software security and quality solutions. Whether you’re a system-on-chip (SoC) designer creating advanced semiconductors, or a software developer writing applications that require the highest security and quality, Synopsys has the solutions needed to deliver innovative, high-quality, secure products. Learn more at www.synopsys.com.

About UMC

UMC (NYSE: UMC, TWSE: 2303) is a leading global semiconductor foundry that provides advanced IC production for applications spanning every major sector of the electronics industry. UMC’s robust foundry solutions enable chip designers to leverage the company’s sophisticated technology and manufacturing, which include high volume production 28nm gate-last High-K/Metal Gate technology, ultra-low power platform processes specifically engineered for Internet of Things (IoT) applications and the automotive industry’s highest-rated AEC-Q100 Grade-0 manufacturing capabilities for production of ICs found in cars. UMC’s 11 wafer fabs are strategically located throughout Asia and are able to produce over 500,000 wafers per month. The company employs nearly 19,000 people worldwide, with offices in Taiwan, China, Europe, Japan, Korea, Singapore, and the United States. UMC can be found on the web at http://www.umc.com.

Editorial Contacts:
Carole Murchison
Synopsys, Inc.   
650-584-4632   
carolem@synopsys.com

Richard Yu
UMC
(886) 2-2658-9168 ext. 16951
richard_yu@umc.com  

 

SOURCE Synopsys, Inc.

New Report Demonstrates The Clinical And Economic Value Of The ATTUNE® Knee System In Today’s Value-Based Environment

SAN DIEGO, March 14, 2017 /PRNewswire/ — Today, DePuy Synthes*, part of the Johnson & Johnson Family of Companies, released a new report, „Improving the Value of Primary Total Knee Arthroplasty: the ATTUNE® Knee System,” that analyzes the ATTUNE Knee’s current clinical and economic data. The report concludes that in a value-based healthcare environment with cost constraints and growing procedure volumes, the value of a knee replacement implant is measured not only by how long the implant lasts (implant survivorship), but also through patient reported outcomes and the economic benefits of the procedure.  

The report, which was released alongside the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, is authored by David Fisher**, M.D., Director of the Total Joint Center of Excellence at OrthoIndy Hospital in Indianapolis, Indiana, and Professor David Parkin, an Honorary Visiting Professor at City, University of London and a Senior Visiting Fellow, Office of Health Economics.

The report analyzes approaches for evaluating primary total knee arthroplasty (TKA) from a clinical and health economic perspective, and assesses the current data from DePuy Synthes’ ATTUNE Knee Evidence Generation Program. This program, the largest of its kind in DePuy Synthes’ history, includes a wide range of data from company-initiated studies, investigator-initiated studies, independent studies and national joint registries.   

In their analysis, Dr. Fisher and Professor Parkin conclude that, „Based on available data, the ATTUNE Knee appears to be advancing outcomes for patients and creating value for clinicians, providers and payors in a challenging and dynamic healthcare environment.”

Click to Tweet: New @DePuySynthes report released today demonstrates the clinical and economic value of the ATTUNE® Knee System #AAOS17 http://bit.ly/2mjUTL8

This report comes at a time when the entire episode of patient care is a major focus for global healthcare providers, placing a laser-like focus on both improving patient outcomes and managing costs. The bundled payments program in the United States and the „Payments for Results” system in England are two examples of the drive to minimize the total cost of care while maintaining quality. Against this backdrop, data from a comprehensive evidence generation program can help provide evidence to support decisions about a device’s overall value.

„The success of any knee replacement is multifactorial, and the data on the ATTUNE Knee gives me confidence that I’m using a knee replacement that is delivering value for patients and the healthcare system,” said Dr. Fisher.

Added Professor Parkin: „Quality of life, as measured by patient reported outcomes, has been shown to be a driver of cost effectiveness in knee replacement. The evidence that I’ve seen about the effectiveness of the ATTUNE Knee in improving patient reported outcomes suggests it can deliver a better quality of life for patients compared to other leading knee systems. Therefore, the ATTUNE Knee may potentially play a role in helping reduce some of the healthcare and societal costs associated with knee osteoarthritis.”

According to the analysis, the ATTUNE Knee has thus far demonstrated favorable survivorship, improved patient reported outcomes versus other knee systems, as well as potential economic benefits:

To read this report and learn more about ATTUNE Knee Evidence, visit www.ATTUNEevidence.com.

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains „forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the effectiveness and value of the ATTUNE Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns for health care products and services; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned „Risk Factors” and „Cautionary Note Regarding Forward-Looking Statements”, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

**Consultant to DePuy Synthes Companies

The third party trademarks used herein are the trademarks of their respective owners.

DSUS/JRC/0217/2031 March 2017

References:

 

SOURCE DePuy Synthes

MEI Pharma to Present at Oppenheimer Healthcare Conference

SAN DIEGO, March 14, 2017 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 21, 2017 at 9:10 a.m. Eastern time from the Westin New York Grand Central. A live webcast of the presentation can be accessed at www.meipharma.com. A replay will be available approximately one hour after the presentation.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. MEI Pharma’s clinical development pipeline also includes ME-401, a potent and highly selective oral PI3K delta inhibitor currently in a Phase Ib study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or follicular lymphoma. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer. For more information, please visit www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are „forward-looking statements” within the meaning of the „safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

 

SOURCE MEI Pharma, Inc.

ConsumerMedical Enters into Agreement with CoreTrust for Medical Decision Support Services

PEMBROKE, Mass., March 14, 2017 /PRNewswire/ — ConsumerMedical, a health care decision support and concierge-company, announced that it has signed an agreement with CoreTrust, a group purchasing organization for large corporations and private equity firms, to support the employee health care needs of CoreTrust’s member companies.

ConsumerMedical serves as a Medical Ally to member organizations, helping their employees make better-informed medical decisions and find quality health care, including physicians and hospitals. The company uses its Five Drivers of Quality™ model to help patients make informed decisions and receive evidence-based care and longitudinal support for their entire health care journey.

„We’re happy to bring our clinical expertise to this collective of organizations in order to help employees of CoreTrust and HealthTrust member companies make informed decisions and receive quality health care,” says Kevin Kickhaefer, Chief Revenue Officer for ConsumerMedical.

By helping employees make better-informed decisions and receive their care from quality providers, ConsumerMedical helps companies manage their spend on health care services. In addition, employees may enjoy better health outcomes and feel more confident in their health care decisions.

About ConsumerMedical
ConsumerMedical is a leading health care decision support and concierge company serving approximately 2 million individuals through some of the nation’s largest employers, health plans and private exchanges. As a Medical Ally, ConsumerMedical guides participants throughout their health care journey with compassionate, high-touch support and deep clinical expertise. ConsumerMedical offers a fully integrated suite of solutions including Medical Decision Support, Expert Medical Opinions, Claims Advocacy and more, helping individuals and families navigate the health care system while reducing unnecessary elective surgeries and driving patients to the highest quality providers. For information is available at www.consumermedical.com.

About CoreTrust
CoreTrust (www.coretrustpg.com) serves an exclusive membership of select private equity firms and Fortune 1000 companies. A division of HealthTrust—the healthcare industry’s leading group purchasing organization—CoreTrust leverages its purchasing volume along with that of HealthTrust members to achieve market-leading pricing for a portfolio of contracts in more than 100 indirect spend categories including human resources employee benefits. This unique and highly-compliant business model affords most members double-digit savings across all categories.

SOURCE ConsumerMedical

Award Winning Actor And Hip-Hop Artist Common Joins Allergan’s See America(SM) Initiative To Further The Fight Against Preventable Blindness

DUBLIN, March 14, 2017 /PRNewswire/ — See America, Allergan’s initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to „stand in the way of darkness”.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8057551-common-joins-allergan-see-america-against-preventable-blindness/

The video harnesses Common’s striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss1, and challenges us all to imagine a life without sight.

„I’m proud to join Allergan in the fight against preventable blindness,” said Common. „Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.”

Common’s involvement echoes the mission of Allergan’s See America initiative by raising awareness to make sure that each and every one of us makes the time to prioritize our vision. Taking steps as simple as regular comprehensive eye exams can help detect eye diseases like glaucoma, diabetic retinopathy or age-related macular degeneration early, before irreversible damage is done.2

On Common’s partnership with See America, „We are excited to have joined forces with Common to raise awareness of the important issue of preventable blindness in America. This video marks the first of many ways in which we aim to educate and engage the public. Common shares our bold approach to life, and we believe that this video will take us one step closer to nationwide appreciation for the gift of sight,” said Herm Cukier, Allergan Senior Vice President of Eye Care.

To watch the video, and to learn more about See America, visit www.SeeAmerica.vision.

ABOUT SEE AMERICA:
Allergan, a global leader in eye care for nearly 70 years, has recently launched See America to fight against preventable blindness and vision impairment in America. See America has set out to make vision health a priority across the U.S., increase awareness of diseases that cause preventable blindness, and bring critical access to vision care to those who need it most. To find out more about See America, visit www.SeeAmerica.vision

ABOUT ALLERGAN PLC.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com

Allergan Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

1CDC_Keep an Eye on Your Vision Health 
2CDC_Keep an Eye on Your Vision Health

CONTACTS:
Media:
Mark Marmur
mark.marmur@allergan.com
+1 (862) 261 7558

Suzanne Jacobson
suzanne.jacobson@allergan.com
+1 (201) 427 8879

Karina Calzadilla
investorrelations@allergan.com
+1 (862) 261 7328

 

SOURCE Allergan

Résultats d’une étude : la filiale de Medical Marijuana, Inc. , HempMeds® Mexico, annonce la publication d’une étude portant sur son produit Real Scientific Hemp Oil-X™ dans le traitement de l’épilepsie chez les enfants

Cette étude conclut que le produit RSHO-X™ au cannabidiol (CBD) est bénéfique et efficace dans le traitement des symptômes de l’épilepsie sévère, et un neurologue mexicain signale une réduction de 84 % des cas signalés de crise d’épilepsie motrice, sept patients signalant une disparition totale des symptômes

SAN DIEGO, 14 mars 2017 /PRNewswire/ — Medical Marijuana, Inc. (MJNA), la toute première société de cannabis cotée en bourse aux États-Unis, a annoncé que sa filiale HempMeds® Mexico tiendra aujourd’hui une conférence de presse à Mexico, au Mexique, afin de communiquer les résultats positifs d’une récente étude menée par le célèbre médecin mexicain, le docteur Saul Garza Morales, sur les effets du produit Real Scientific Hemp Oil-X™ (RSHO-X™) de la société dans le traitement des enfants atteints d’épilepsie sévère.

Cette étude, qui a été menée par le neurologue en pédiatrie mexicain, le docteur Garza, a porté sur 39 patients atteints du syndrome de Lennox-Gastaut, une forme grave d’épilepsie pédiatrique qui survient habituellement vers l’âge de 4 ans. Sur ces 39 patients, qui ont pris des doses progressives de RSHO-X™ 5000MG allant jusqu’à 5-7mg CBD/kg, 84 % ont observé une réduction des crises d’épilepsie motrice ; 53 % ont signalé une réduction de plus de 75 % des crises ; et 7 ont signalé une disparition totale de toutes les crises sur une période de 4 mois, avec aucun effet secondaire signalé.

« Les résultats de cette étude sont très encourageants, car ils montrent les meilleurs résultats de l’un quelconque produit/médicament jamais enregistrés pour la réduction des crises d’épilepsie chez les patients atteints du syndrome de Lennox-Gastaut, 17 % des patients visés par l’étude ayant observé une disparition totale de leurs crises », explique le PDG de Medical Marijuana, Inc., le docteur  Stuart Titus. « Les études qui démontrent les atouts thérapeutiques de CBD sont vitales, puisqu’elles continueront de favoriser des programmes de cannabis à usage thérapeutique moins restrictifs, pas seulement au Mexique, mais dans le monde entier. C’est une nouvelle très encourageante pour les enfants qui sont atteints d’une forme aussi grave d’épilepsie et qui disposent dorénavant d’une option thérapeutique, alors que le diagnostic était auparavant peu optimiste puisqu’il n’existait aucun signe de traitement bénéfique une fois que l’épilepsie était entrée dans sa phrase dite réfractaire (pharmaco-résistante) ».

« L’étude du docteur Garza représente une victoire écrasante de la CBD botanique sur la solution pharmaceutique », ajoute le docteur Titus. « Nous croyons fermement à l’effet d’entourage du produit botanique naturel, aussi bien en termes d’innocuité que d’efficacité ».

En outre, l’étude a fait apparaître une augmentation par deux de la réduction de nombre de crises par rapport à l’Epidiolex de GW Pharmaceuticals – avec ZERO effet secondaire néfaste. En revanche, 79 % des enfants qui ont participé à l’étude sur l’Epidiolex de GW ont signalé des effets secondaires, et 30 % ont signalé des effets secondaires graves. Pour de plus amples informations sur l’étude GW Pharmaceuticals, consultez ce rapport.

Le zero-Tetrahydrocannabinol (THC) RSHO-X™ de HempMeds® Mexico a été le tout premier produit à base de cannabis à être agréé pour l’importation par le Gouvernement central du Mexique, COFEPRIS. RSHO-X™ est également le premier produit à base de cannabis à être considéré comme sûr au regard des normes antidopage mondiales, et il peut par conséquent être utilisé sans crainte par les athlètes olympiques ou ceux qui font régulièrement l’objet de tests de dépistage du THC ou du THC synthétique, comme le personnel militaire en activité et à la retraite, les premiers intervenants, comme la police, les pompiers, et les techniciens urgentistes, ou quiconque doit se soumettre à un test de dépistage.

Les résultats de cette étude seront publiés prochainement. Pour consulter l’étude, cliquez ici.

A propos de Medical Marijuana, Inc.
Notre mission est d’être le principal innovateur du secteur du cannabis et de la marijuana, en tirant profit de notre équipe de professionnels pour nous procurer, évaluer et acquérir des entreprises et des produits à valeur ajoutée, tout en leur permettant de conserver leur intégrité et leur esprit d’entreprise. Nous nous efforçons de sensibiliser notre secteur, de développer des entreprises respectueuses de l’environnement et durables sur le plan économique, tout en augmentant la valeur pour les actionnaires. Pour en savoir plus sur les sociétés de portefeuille et d’investissement de Medical Marijuana, Inc., veuillez visiter www.medicalmarijuanainc.com.

Pour voir la déclaration vidéo de Medical Marijuana, Inc., veuillez cliquer ici. Les actionnaires sont également invités à visiter la boutique de Medical Marijuana, Inc. pour obtenir des produits à des prix réduits.

CLAUSE PROSPECTIVE DE NON RESPONSABILITÉ
Ce communiqué de presse peut contenir certaines déclarations et certaines informations prospectives, au sens où l’entend la Section 27A de la loi Securities Act de 1933 et la Section 21E de la loi Securities Exchange Act de 1934, et il est soumis aux principes de la sphère de sécurité édictés par lesdites sections. Ce document contient des énoncés concernant des événements et/ou des résultats financiers futurs attendus qui sont de nature prospective et qui sont sujets à des risques et des incertitudes.

De tels énoncés impliquent par définition des risques et des incertitudes. Les énoncés de ce communiqué de presse n’ont pas été évalués par la Food and Drug Administration (FDA) et ne sont pas destinés à diagnostiquer, traiter ou soigner une maladie quelconque. L’entreprise ne vend pas ou ne distribue pas des produits qui enfreignent la loi Controlled Substances Act des États-Unis. L’entreprise ne vend pas ou ne distribue pas des produits à base de marijuana.

CONTACT :
Contact pour les relations publiques : 
Andrew Hard
Président-directeur général
CMW Media
P: 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Photo – http://mma.prnewswire.com/media/478204/Medical_Marijuana_Study_Infographic.jpg

SOURCE Medical Marijuana, Inc.

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

JACKSONVILLE, Fla., March 14, 2017 /PRNewswire/ — TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).  If successful, TapImmune’s vaccine may replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women.

„This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication,” said Dr. Glynn Wilson, chairman and CEO of TapImmune. „In addition to ongoing and planned Phase 2 studies of our lead TPIV 200 vaccine for treating triple-negative breast cancer, this new study of our HER2neu vaccine in DCIS has the potential to validate our novel approach to establishing lasting immunity against breast cancer and precancerous lesions. Her2neu is overexpressed in about 30% of all breast cancer patients amounting to approximately 220,00 patients per year.  We look forward to the advancement of this fully funded study, as it further broadens our robust clinical pipeline, which also includes two additional Phase 2 trials for treating ovarian cancer.”

The study is expected to begin in 2017 and will be led by Keith Knutson, Ph.D., Director of the Discovery and Translational Labs Cancer Research Program at Mayo Clinic’s Florida campus.  It is expected to enroll 40-45 women with DCIS, who will receive the vaccine six weeks prior to standard surgical resection.  The vaccine has already been shown to stimulate production of T-cells directed against breast cancer cells that overexpress the oncogene HER2 in a completed Phase 1 study.  

TapImmune has licensed the HER2neu vaccine technology that will be used in this study and has the worldwide exclusive rights to commercialize the technology.  TapImmune will be funded for providing the manufactured product for this trial.

Dr. Knutson added, „DCIS is a significant health problem, accounting for about 20% of U.S. cases of breast cancer. We ultimately want to eliminate ductal carcinoma in situ, which means preventing disfiguring surgeries and toxic therapies in the 60,000 women who receive this diagnosis every year in the U.S.”

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman’s cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient’s killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company’s technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company’s website at www.tapimmune.com for more details. 

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are „forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements. 


 

SOURCE TapImmune, Inc.

New Survey Reveals Impact Of Double Chin On Self-Perception And Behavior

DUBLIN, March 14, 2017 /PRNewswire/ — Results of a recent survey commissioned by Allergan plc to better understand the personal impact of submental fullness as well as how others perceive individuals with submental fullness were revealed at the American Academy of Dermatology (AAD) Meeting in Orlando, FL. 1,996 men and women in the U.S. between the ages of 18 and 65 were surveyed to better understand how having a double chin plays a role in self-perception and alternatively, how those with submental fullness are viewed by others.1

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8061651-allergan-kybella-double-chin-survey/

Results of the survey revealed:

Impact of Submental Fullness on Self-Perception, Behavior and Social Perceptions

„We understand that submental fullness is a common concern,4” says David Moatazedi, Senior Vice-President of Facial Aesthetics at Allergan. „It was important for us to dig deeper to better understand the substantial impact that submental fullness may have on patients’ self-perception and behavior, as well as the perception others may have of individuals with submental fullness. Gaining a better understanding of how having a double chin plays a role in self-perception and alternatively, how those with submental fullness are viewed by others will help physicians in their daily interactions with these patients.”

„The results of this survey mimic what I hear from patients on a daily basis – they are bothered by submental fullness and are looking to address the problem. In many cases, the submental fullness is genetic and resistant to diet or exercise,2,3” says Dr. Shannon Humphrey, Board-Certified Dermatologist and Co-Author of this survey. „These findings will help physicians to better understand the impact a double chin has on our patients so we can address this issue and provide them with effective treatment options.”

Allergan is the maker of KYBELLA® (deoxycholic acid) injection 10 mg/mL, the only FDA-approved injectable treatment for adults that destroys fat cells in the treatment area under the chin to improve a patient’s profile – whether they have a moderate amount of chin fullness or a bit more – with no surgery.5 The active ingredient in KYBELLA® is a non-human, non-animal formulation of deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.6 When injected into the fat in the treatment area beneath the chin, KYBELLA® physically destroys fat cells, which makes them unable to accumulate or store fat. 5,6 

In clinical studies, 88% of patients received more than one KYBELLA® treatment,7,8 with 59% of patients receiving six KYBELLA® treatments. Everyone has a different level of submental fat and a licensed and trained physician will be able to determine the number of KYBELLA® treatments each patient will need. Multiple injections are given under the chin per treatment and up to 6 treatments can be administered, spaced at least 1 month apart. With KYBELLA®, once the desired result is achieved, retreatment is not expected.5 For more information about KYBELLA® or to find a doctor, please visit www.mykybella.com.

KYBELLA® Indication and Important Safety Information

What is KYBELLA®?
KYBELLA® is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called „double chin.”

It is not known if KYBELLA® is safe and effective for use outside of the submental area or in children under the age of 18.

Who should not receive KYBELLA®?
You should not receive KYBELLA® if you have an infection in the treatment area.

Before receiving KYBELLA®, tell your healthcare provider about all of your medical conditions, including if you: Have had or plan to have surgery on your face, neck, or chin; have had cosmetic treatments on your face, neck, or chin; have had or have medical conditions in or near the neck area; have had or have trouble swallowing; have bleeding problems; are pregnant or plan to become pregnant (it is not known if KYBELLA® will harm your unborn baby); are breastfeeding or plan to breastfeed (it is not known if KYBELLA® passes into your breast milk; talk to your healthcare provider about the best way to feed your baby if you receive KYBELLA®).

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).

What are the possible side effects of KYBELLA®?
KYBELLA® can cause serious side effects, including nerve injury in the jaw (which can cause an uneven smile or facial muscle weakness), or trouble swallowing.

The most common side effects of KYBELLA® include: swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area.

These are not all of the possible side effects of KYBELLA®. Call your healthcare provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or call 1-800-FDA-1088.

Please talk to your healthcare provider or visit www.mykybella.com for full Prescribing Information.

© 2017 Allergan.  All rights reserved.  All trademarks are the property of their respective owners.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.

Allergan Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

References:

1. Allergan, Data on File, Submental Fullness Survey, April 2016.
2. Defatta, Robert, „Liposuction of the Face and Neck”, 2007.
3. Schlessinger, Joel, „Perceptions and Practices in Submental Fat Treatment: A Survey of Physicians and Patients”, SkinMed, Jan/Feb 2013.
4. American Society for Dermatologic Surgery 2015 Consumer Survey on Cosmetic Dermatologic Procedures, 2015. „How Bothered Are You By Excess Fat Under The Chin/Neck?”
5. KYBELLA® Prescribing Information, 2015.
6. Thuangtong R, Bentow J, Knopp K, Mahmood N, David N, Kolodney M. Tissue-Selective Effects of Injected Deoxycholate. American Society for Dermatologic Surgery, Inc. 2010; 36(6):899-908.
7. Data On File, ATX-101-11-22 Clinical Study Report.
8. Data On File, ATX-101-11-23 Clinical Study Report.

CONTACTS:                                     
Investors:
Karina Calzadilla                                                                                  
(862) 261-7328

Media:
Mark Marmur
(862) 261-7558

Ember Garrett
(714) 246-3525

 

SOURCE Allergan plc